-
Product Insights
Jilin Jiutai Biomass Power Plant
Jilin Jiutai Biomass Power Plant is a biopower project located in Jilin, China. The project is currently active. Empower your strategies with our Jilin Jiutai Biomass Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and...
-
Product Insights
Jiutai Coal Fired Power Plant
Jiutai Coal Fired Power Plant is a thermal project located in Jilin, China. The project is owned by Huaneng Power International Inc. The project came online in 2009. Empower your strategies with our Jiutai Coal Fired Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report...
-
Product Insights
Jiutai Energy Inner Mongolia Company Ordos Barun Gar Domda Complex, China
Jiutai Energy Inner Mongolia Company Ordos Barun Gar Domda Complex is located in Inner Mongolia, China. It started operations in 2010. Empower your strategies with our Jiutai Energy Inner Mongolia Company Ordos Barun Gar Domda Complex, China report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may...
-
Sector Analysis
Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition
According to the Global Data’s Drugs database, it indicates that maximum of the marketed drugs is found to be small molecules, despite many of the prominent contract manufacturing organizations (CMOs) investing in advanced therapy medicinal product (ATMP) capabilities in recent years and an increasing use of biologic APIs in both the pipeline and among marketed drugs. With the increase in high potency small molecule APIs, has been driven by the rise of oncology pipeline drugs coupled with small or virtual...